ClinicalTrials.gov record
Completed Phase 3 Interventional

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

ClinicalTrials.gov ID: NCT00135395

Public ClinicalTrials.gov record NCT00135395. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIIb, Open -Label, Randomized Multi-center Study Comparing the Antiviral Efficacy, Safety, and Effect on Serum Lipids of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, in Combination With Two Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in HIV-1 Infected Subjects Experiencing Their First Virologic Failure While Receiving a NNRTI-containing HAART Regimen.

Study identification

NCT ID
NCT00135395
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
200 participants

Conditions and interventions

Conditions

Interventions

  • Atazanavir+ritonavir Drug
  • Lopinavir+ritonavir Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2004
Primary completion
Jan 31, 2006
Completion
Jan 31, 2006
Last update posted
Feb 4, 2010

2004 – 2006

United States locations

U.S. sites
52
U.S. states
25
U.S. cities
52
Facility City State ZIP Site status
Local Institution Hobson City Alabama
Local Institution Montgomery Alabama
Local Institution Phoenix Arizona
Local Institution Little Rock Arkansas
Local Institution Bakersfield California
Local Institution Los Angeles California
Local Institution San Francisco California
Local Institution San Mateo California
Local Institution Tarzana California
Local Institution West Hollywood California
Local Institution Norwalk Connecticut
Local Institution Washington D.C. District of Columbia
Local Institution Atlantis Florida
Local Institution Fort Lauderdale Florida
Local Institution Jacksonville Florida
Local Institution Miami Florida
Local Institution Miami Beach Florida
Local Institution North Miami Florida
Local Institution Orlando Florida
Local Institution Plantation Florida
Local Institution Safety Harbor Florida
Local Institution Tampa Florida
Local Institution Atlanta Georgia
Local Institution Decatur Georgia
Local Institution Chicago Illinois
Local Institution Indianapolis Indiana
Local Institution Louisville Kentucky
Local Institution New Orleans Louisiana
Local Institution Boston Massachusetts
Local Institution Springfield Massachusetts
Local Institution Berkley Michigan
Local Institution Jackson Mississippi
Local Institution St Louis Missouri
Local Institution Las Vegas Nevada
Local Institution East Orange New Jersey
Local Institution Hillsborough New Jersey
Local Institution Jersey City New Jersey
Local Institution Brooklyn New York
Local Institution Mount Vernon New York
Local Institution New York New York
Local Institution Valhalla New York
Local Institution Greenville North Carolina
Local Institution Huntersville North Carolina
Local Institution Winston-Salem North Carolina
Local Institution Oklahoma City Oklahoma
Local Institution Philadelphia Pennsylvania
Local Institution Columbia South Carolina
Local Institution Dallas Texas
Local Institution Galveston Texas
Local Institution Harlingen Texas
Local Institution Houston Texas
Local Institution Hampton Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00135395, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 4, 2010 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00135395 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →